Amyloidosis – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of amyloidosis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of amyloidosis for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan.

Clarivate Epidemiology’s amyloidosis forecast will answer the following questions:

  • Of all people diagnosed with amyloidosis, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of amyloidosis over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 15 amyloidosis patient populations, as follows:

  • Diagnosed incident cases of amyloidosis.
  • Diagnosed prevalent cases of amyloidosis.
  • Diagnosed incident cases of amyloid light chain (AL) amyloidosis.
  • Diagnosed prevalent cases of AL amyloidosis.
  • Diagnosed incident cases of amyloid A (AA) amyloidosis.
  • Diagnosed prevalent cases of AA amyloidosis.
  • Diagnosed incident cases of hereditary transthyretin amyloidosis (hATTR).
  • Diagnosed prevalent cases of hATTR.
  • Diagnosed incident cases of wild-type transthyretin amyloidosis (wtATTR).
  • Diagnosed prevalent cases of wtATTR.
  • Diagnosed incident cases of hATTR familial amyloid polyneuropathy (FAP) amyloidosis.
  • Diagnosed prevalent cases of hATTR FAP amyloidosis.
  • Diagnosed incident cases of hATTR familial amyloid cardiomyopathy (FAC) amyloidosis.
  • Diagnosed prevalent cases of hATTR FAC amyloidosis.
  • Diagnosed drug-treated prevalent cases of amyloidosis.

Note: Coverage may vary by country.